Safety of Anal Curcumin
Recruiting now · Phase 1
Conditions studied: Anal High Grade Squamous Intraepithelial Lesion
In brief
The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.
Key facts
- Study ID
- NCT06626230
- Run by
- Lisa Flowers
- People needed
- 48
- Starts
- 2025-03-17
- Expected to finish
- 2026-07-01
- Last updated by the study team
- 2026-05-18
Who can join
Age: 30 and older. Sex: any. Healthy volunteers: accepted.
You may not qualify if…
- Have a clinically significant chronic medical condition that is considered progressive, such as but not limited to coronary disease, congestive heart failure, chronic obstructive lung disease, and diabetes mellitus. Chronic nonprogressive or intermittent syndromes are not excluded, including migraine headaches, mild reactive airway disease, controlled hypertension, stable pain syndromes, or benign gastric reflux.
- Have any history of anal cancer malignancy.
- Pregnant or planning to become pregnant in the next three months.
- Have a history of sensitivity or allergy to any compound used in this study.
- Have Grade 2 or higher renal or hematology abnormality,
- Are currently using, or in the last year have used intravenous drugs (except for therapeutic use), recreational drugs, or alcohol abuse.
- Other exclusion criteria apply
Where it is running
- Grady Memorial Hospital — Atlanta, Georgia, United States (enrolling)
- Grady Hospital - Ponce De Leon Clinic — Atlanta, Georgia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.